Conference Track

Genitourinary Cancers

Source: CCO Independent Conference Coverage of the 2008 American Society of Clinical Oncology Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Carboplatin Proves Safe and Effective in Adjuvant Setting for Treatment of Stage I Seminoma Patients: Lower Incidence of Contralateral Testicular Germ Cell Cancer
Satraplatin Reduces Risk of Disease Progression but Does Not Improve Survival in Men With HRPC Progressing After Previous Chemotherapy
Abiraterone Acetate Demonstrates Antitumor Activity in Patients With Castration-Resistant Prostate Cancer
Sunitinib Improves Survival Compared With Interferon alfa in Patients With Metastatic Renal Cell Carcinoma
Bevacizumab Plus Interferon Improves PFS in RCC Irrespective of Histology, VEGF, or Renal Function (AVOREN Subgroup Analysis)
Phase III RECORD-1 Trial: Everolimus Improves PFS in Patients With Metastatic Renal Cell Carcinoma Progressing After VEGFR TKI therapy
Vinflunine Impacts Survival in Second-Line Treatment for Advanced Transitional Cell Carcinoma of the Urothelium
In Second-Line Treatment of Advanced Bladder Cancer, Gemcitabine/Paclitaxel Until Progression Fails to Show Survival Benefit vs Finite 6 Cycles of Therapy
IFN alfa + IL-2 + 5-FU Improves Response But Not Survival in Patients With Metastatic Renal Cell Carcinoma
Profiling of Peripheral Blood Gene Expression Used to Distinguish Bladder Cancer From Benign Bladder Conditions

Expert Analysis

Genitourinary Cancers

Program Director: Ramaswamy Govindan, MD

Faculty:

David I. Quinn, MD, PhD
Brian I. Rini, MD
Nicholas J. Vogelzang, MD

Robert S. Mocharnuk, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize data from recent studies regarding current standards of care for patients with genitourinary cancer
Describe new data on novel agents and therapeutic approaches for patients with genitourinary cancer
Identify new agents and treatment strategies appropriate for the clinical management of patients with genitourinary cancer

CREDIT INFORMATION

Release Date: August 19, 2008

Expiration Date: August 18, 2009

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.1 Nursing contact hours

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.